ChromaVision Reports First Commercial Placement of Automated Cellular Imaging System With COBE BCT.SAN JUAN CAPISTRANO San Juan Capistrano (săn wän kăpĭsträ`nō), city (1990 pop. 26,183), Orange co., S Calif.; inc. 1961. San Juan Capistrano has some manufactures, including aircraft parts, medical apparatus, and boats, but the economy is , Calif.--(BW HealthWire)--Aug. 18, 1998-- ChromaVision Medical Systems Inc. (Nasdaq NM:CVSN) Tuesday announced the first commercial placement of its Automated Cellular Imaging System (ACIS(TM)) with COBE COBE: see infrared astronomy. BCT BCT Brigade Combat Team BCT Basic Combat Training BCT Best Conventional Pollutant Control Technology (EPA) BCT Business Cards Tomorrow BCT Banque Centrale de Tunisie (Central Bank of Tunisia) Inc.(R) of Lakewood, Colo., a part of Gambro, a global company in medical technology and healthcare services. COBE(R) BCT(TM) is a leading developer and distributor of blood purification and separation systems for patients requiring bone marrow and stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. transplants to fight life threatening diseases including cancer, aplasticanemia, and severe immune deficiencies. COBE BCT's decision to use the ACIS was based on the findings of a study that determined the system to be nearly three times more effective in detecting tumor cells than traditional manual microscopy methods (87.8 percent vs. 31 percent respectively). Further, the speed of the ACIS reduced specimen analysis time significantly. Douglas Harrington, M.D., chief executive officer of ChromaVision, stated: "We are excited about our agreement with COBE BCT and the impact our combined technologies may have on improving the quality of patient care. The COBE BCT selection of the ACIS is an important vote of confidence in the ability of our advanced cellular imaging technology to detect rare events." The sensitivity of the ACIS in detecting tumor cells or occult metastases Metastasis (plural, metastases) A tumor growth or deposit that has spread via lymph or blood to an area of the body remote from the primary tumor. Mentioned in: Malignant Melanoma also has important ramifications ramifications npl → Auswirkungen pl for patients suffering from breast, lung and colorectal cancers. A study under the direction of Dr. Richard Cote, M.D., at the University of Southern California's Kenneth Norris Cancer Center has shown the ACIS to be an effective tool in the early detection of the spread of certain types of lung cancers. The system can identify the migration of cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer , known as occult metastases, to bone marrow. The detection of these cells is viewed to be a potentially more accurate indicator of disease reoccurrence than existing tests, and is expected to guide more effective therapies, thereby avoiding over- or under-treatment. About the ACIS and ChromaVision The ACIS combines color-based imaging software with automated robotic microscopy to evaluate a variety of cellular conditions, including cancer detection and staging, quantitative viral load viral load n. The concentration of a virus, such as HIV, in the blood. viral load, n a measure of the number of virus particles present in the bloodstream, expressed as copies per milliliter. for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , and prenatal screening for a range of genetic disorders. The company currently markets its products to research centers, university medical centers and commercial laboratories throughout the world. Founded in 1993 as a division of XL Vision Inc., ChromaVision made its initial public offering in August 1997, and is a Safeguard Scientifics Inc. partnership company. About COBE BCT Inc. COBE Blood Component Technology (BCT) delivers blood separation and purification systems that collect and process blood components for treatment of patients with a wide range of ailments. COBE BCT Inc. is a part of Gambro, a global company in medical-technology and healthcare services with leading positions in renal dialysis products and related services, cardiovascular surgery cardiovascular surgery Heart surgery An operation for repairing structural defects of the cardiovascular system Examples CABG, repair of congenital heart defects, varicose veins, aortic aneurysms, ventricular remodeling, transmyocardial products and blood component technology. Gambro has over 17,000 employees in 90 subsidiaries in 26 countries. The statements contained herein regarding ChromaVision Medical Systems Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainty of success in developing any new diagnostic test, failure to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance or approval for particular applications and dependence on third parties for clinical testing. ACIS is a trademark of ChromaVision Medical Systems Inc.
CONTACT: Allen & Caron Inc.
Matt Clawson (investors)
Owen Daley (media)
714/957-8440
or
ChromaVision Medical Systems Inc.
Kevin O'Boyle, vice president, CFO
949/443-3355
koboyle@chromavision.com
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion